282 related articles for article (PubMed ID: 20642545)
1. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
4. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
[TBL] [Abstract][Full Text] [Related]
6. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
Landersdorfer CB; He YL; Jusko WJ
Br J Clin Pharmacol; 2012 Mar; 73(3):373-90. PubMed ID: 22442825
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
[TBL] [Abstract][Full Text] [Related]
11. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
[TBL] [Abstract][Full Text] [Related]
13. Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.
Wu T; Zhang X; Trahair LG; Bound MJ; Little TJ; Deacon CF; Horowitz M; Jones KL; Rayner CK
J Clin Endocrinol Metab; 2016 Dec; 101(12):4769-4778. PubMed ID: 27598511
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
15. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
16. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
[TBL] [Abstract][Full Text] [Related]
18. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
19. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
20. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
